Photo from Giampaolo Bianchini/Twitter
May 8, 2024, 23:17
Giampaolo Bianchini: Join us at the next ESMO Virtual Plenary session!
Elisa Agostinetto, Research Physician at Institute of Jules Bordet in Brussels, shared a post by Giampaolo Bianchini, Head of the Translational and Immunotherapy Research Group at the San Raffaele Scientific Institute – Milan, on X, adding the following:
“Results from a randomized phase 3 trial will be presented this Thursday at the ESMO Virtual Plenary – intriguing data for all breast oncologists!!”
Quoting Giampaolo Bianchini’s post:
“Join us at the next ESMO Virtual Plenary session!
- Is there a new PARPi option for HER2-neg gBRCA1/2mut MBC?
- Does a combination of PARPi and antiangiogenic drug (apatinib) improve efficacy?
- Are VEGFRi better than bevacizumab?”
Source: Elisa Agostinetto/X and Giampaolo Bianchini/X
antiangiogenic therapy
Bevacizumab
breast oncology
cancer
clinical trial
Elisa Agostinetto
ESMO
ESMO Virtual Plenary
gBRCA1/2 mutation
Giampaolo Bianchini
HER2-negative
Institute of Jules Bordet
metastatic breast cancer
OncoDaily
Oncology
PARP inhibitors
Research
San Raffaele Scientific Institute
VEGFR inhibitors
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 10:45
Feb 21, 2025, 10:07
Feb 21, 2025, 09:58
Feb 21, 2025, 09:54
Feb 21, 2025, 09:45
Feb 21, 2025, 09:35